ABL Bio Inc
Company Profile
Business description
ABL Bio Inc is a Korean biotech research company. The company is engaged in the research and development of bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases. It develops therapeutic candidates using its bispecific antibody technology platforms. In the neurodegenerative disorder space, the company develops therapeutics for CNS-related diseases utilizing Grabody-B and Grabody-T for oncology applications. The company's pipeline includes candidates such as ABL111, ABL503, ABL105, ABL104, AB103, etc. The company is also developing bispecific antibody-drug conjugate (ADC) technologies and related therapeutic candidates.
Contact
2nd Floor, 16 Daewangpangyo-Ro 712
Beon-Gil, Bundang-Gu
Gyeonggi-do
Seongnam-si13488
KORT: +82 3180189800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
105
Stocks News & Analysis
stocks
Australia’s oldest REIT undervalued
stocks
Stop asking if there’s a stock market bubble. Ask this instead.
stocks
Are negative AI narratives holding this ASX share back?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,931.40 | 71.60 | -0.80% |
| CAC 40 | 8,337.29 | 66.70 | -0.79% |
| DAX 40 | 25,040.28 | 44.47 | 0.18% |
| Dow JONES (US) | 52,305.24 | 13.96 | -0.03% |
| FTSE 100 | 10,478.34 | 18.78 | -0.18% |
| HKSE | 22,881.02 | 145.66 | -0.63% |
| NASDAQ | 26,040.03 | 173.69 | -0.66% |
| Nikkei 225 | 70,474.96 | 412.64 | 0.59% |
| NZX 50 Index | 13,609.79 | 0.71 | -0.01% |
| S&P 500 | 7,483.23 | 16.13 | -0.22% |
| S&P/ASX 200 | 8,722.90 | 71.70 | -0.82% |
| SSE Composite Index | 4,094.40 | 20.50 | 0.50% |